Search results
Showing 616 to 630 of 2548 results for methods
In development Reference number: GID-TA11094 Expected publication date: TBC
Awaiting development Reference number: GID-TA10972 Expected publication date: TBC
Awaiting development Reference number: GID-TA10519 Expected publication date: TBC
Tislelizumab with chemoradiation for treating localised oesophageal squamous cell cancer [ID5077]
Awaiting development Reference number: GID-TA10971 Expected publication date: TBC
STG320 for treating allergic rhinitis or rhinoconjunctivitis caused by house dust mites [ID1278]
Awaiting development Reference number: GID-TA10279 Expected publication date: TBC
In development Reference number: GID-TA11760 Expected publication date: TBC
Netarsudil for treating open angle glaucoma or ocular hypertension [ID1078]
Awaiting development Reference number: GID-TA10431 Expected publication date: TBC
Pembrolizumab with axitinib for untreated advanced renal cell carcinoma (TA650)
Evidence-based recommendations on pembrolizumab (Keytruda) with axitinib (Inlyta) for untreated advanced renal cell carcinoma in adults.
Urinary tract infection in under 16s: diagnosis and management (NG224)
This guideline covers diagnosing and managing first or recurrent upper or lower urinary tract infection (UTI) in babies, children and young people under 16. It aims to achieve more consistent clinical practice, based on accurate diagnosis and effective management. It does not cover babies, children and young people with urinary catheters in situ, neurogenic bladders, significant pre-existing urinary tract disorders (uropathies), underlying renal disease or immunosuppression, or recurrent UTI in sexually active girls and young women under 16. It also does not cover babies, children and young people in intensive care units.
Acalabrutinib with venetoclax and obinutuzumab for untreated chronic lymphocytic leukaemia [ID6156]
Awaiting development Reference number: GID-TA11087 Expected publication date: TBC
Denecimig (Mim8) for preventing bleeding episodes in haemophilia A in people 1 year and over ID6400
Awaiting development Reference number: GID-TA11509 Expected publication date: TBC
Neuropathic pain in adults: pharmacological management in non-specialist settings (CG173)
This guideline covers managing neuropathic pain (nerve pain) with pharmacological treatments (drugs) in adults in non-specialist settings. It aims to improve quality of life for people with conditions such as neuralgia, shingles and diabetic neuropathy by reducing pain and promoting increased participation in all aspects of daily living. The guideline sets out how drug treatments for neuropathic pain differ from traditional pain management.
Bifikafusp alfa–onfekafusp alfa for neoadjuvant treatment of 3B or 3C resectable melanoma [ID6384]
Awaiting development Reference number: GID-TA11458 Expected publication date: TBC
Awaiting development Reference number: GID-TA10777 Expected publication date: TBC
Awaiting development Reference number: GID-TA10346 Expected publication date: TBC